Dermatomyositis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions.
Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Dermatomyositis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 29 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dermatomyositis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dermatomyositis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dermatomyositis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adienne Pharma & Biotech SAAlexion Pharmaceuticals Inc
Arctic Therapeutics ehf
Argenx SE
Avotres Inc
Biotech Pharmaceutical Co Ltd
Cabaletta Bio Inc
Cellular Biomedicine Group Ltd
Chongqing Precision Biotech Co Ltd
CSL Ltd
Ermium Therapeutics SAS
Fresh Tracks Therapeutics Inc
Friedrich-Alexander-University Erlangen-Nuremberg
Galapagos NV
GNI Group Ltd
Horizon Therapeutics Plc
ImmunoForge Co Ltd
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
Kyverna Therapeutics Inc
Merck KGaA
NovelMed Therapeutics Inc
Paean Biotechnology Inc
Peking University People's Hospital
Pfizer Inc
Priovant Therapeutics Inc
Santhera Pharmaceuticals Holding AG
Ventus Therapeutics Inc
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Dermatomyositis reports